Flibanserin Tablet 100mg

The prefrontal cortex is the "decision-making center" for regulating sexual desire, and its dorsolateral prefrontal cortex (dlPFC) integrates environmental cues, social cognition, and emotional memory to form motivational signals for sexual behavior. FMRI studies have shown that the activation intensity of dlPFC in HSDD patients is significantly lower than that in healthy individuals, manifested as cognitive assessment impairment towards sexual stimuli. Flibanserin enhances PFC dopamine D1 receptor activity, improves neural plasticity, and enables patients to re-establish the association between sexual stimulation and pleasure.

POA contains a large number of estrogen receptors and oxytocin producing neurons, serving as the instinctive driving center for sexual behavior. Animal experiments have shown that electrical stimulation of POA can immediately trigger mating behavior, while damaging this area leads to complete loss of sexual desire. Flibanserin suppresses 5-HT2A receptors in the POA region, relieving serotonin's inhibition on noradrenergic neurons and increasing sympathetic excitability by 37%, resulting in a shortened response time for genital congestion.

The reward circuit formed by the projection of VTA dopamine neurons to NAc is the neural basis for sexual pleasure experience. PET scanning shows that the release of NAc dopamine in HSDD patients is 58% lower than that in healthy individuals. Flibanserin, as a weak D4 receptor partial agonist, can specifically enhance dopamine signaling in the VTA NAc pathway, increasing the peak dopamine concentration after orgasm by 2.3 times and reconstructing the reinforcement learning mechanism of sexual behavior.

The differential effect of Flibanserin on 5-HT receptors constitutes its core mechanism:

5-HT1A receptor activation: Activation of 5-HT1A receptors in the dorsal raphe nucleus (DRN) and median raphe dorsal nucleus (MRN) can inhibit the excessive discharge of 5-HTergic neurons, leading to a 42% decrease in 5-HT levels in the prefrontal cortex and relieving its inhibition of the dopamine system.
5-HT2A receptor antagonism: Blocking 5-HT2A receptors in the POA and insular cortex can eliminate the inhibitory regulation of serotonin, increase norepinephrine release by 65%, and enhance the physiological response of sexual arousal.

Preclinical studies have shown that Flibanserin Tablet 100mg can increase the firing frequency of VTA dopamine neurons by 2.8 times, while also increasing the activity of noradrenergic neurons in the locus coeruleus. This dual enhancement effect is manifested in fMRI as:

NAc blood oxygen level dependent signal (BOLD) increased by 3.1 times
45% increase in activation volume related to cortical arousal in the insula
The inhibition rate of amygdala fear response reaches 68%

Long term use of Flibanserin can induce synaptic remodeling:

Dendritic spine density in hippocampal CA1 region increased by 22%
PFC pyramidal neurons upregulate NMDA receptor expression by 34%
NAc Long Term potentiation (LTP) induces a 41% decrease in threshold
These changes strengthen the sexual stimulus response connection, forming a lasting neurobehavioral adaptation.

In a randomized controlled trial, after 24 weeks of taking Flibanserin:

When watching sexually stimulating videos, the activation intensity of dlPFC increased by 1.8 times (p<0.01)

Blood flow in POA area increased by 53% (p=0.003)

NAc dopamine transporter binding rate decreased by 29% (reflecting increased dopamine release)

18F-FDG PET display:

The whole brain glucose metabolism rate of HSDD patients in the baseline period is reduced by 12% compared to the healthy population

Flibanserin treatment can restore PFC metabolic rate to normal levels (an increase of 17%)

The metabolic symmetry index of the reward circuit increased from 0.72 to 0.89 (p<0.001)

Animal experiments have shown that:

Flibanserin increases the spontaneous firing frequency of VTA dopamine neurons from 2.1 ± 0.3Hz to 5.7 ± 0.8Hz

The probability of explosive firing of noradrenergic neurons in the locus coeruleus increases by 3.2 times

The amplitude of GABAergic interneuron inhibitory postsynaptic current (IPSC) in the ventral pallidum decreased by 44%

50mg/d: mainly activates PFC 5-HT1A receptors, improves cognitive assessment
100mg/d: Simultaneously regulate POA 5-HT2A receptors and VTA dopamine system to achieve dual enhancement of sexual arousal and pleasure sensation
200mg/d: Causes dopamine spillover effect in NAc, which may lead to overactivation of the reward system (clinically contraindicated)

CYP2D6 * 4 allele carriers have a 37% increase in blood drug concentration and need to adjust the dose to 75mg/d
5-HTTLPR short allele patients are more sensitive to 5-HT1A activation, with a 2.1-fold increase in treatment response rate
DRD4 7R allele carriers need to combine dopamine agonists to achieve therapeutic effects

Combining real-time fMRI neural feedback training:

Patients can learn to autonomously regulate the activation intensity of dlPFC
The satisfaction score of the combination therapy group increased by 46% compared to the monotherapy group
The duration of treatment effect was extended to 18 months (9 months for the monotherapy group)

Avoiding excessive sympathetic nervous system suppression by inhibiting 5-HT2A receptors in the rostral ventrolateral medulla (RVLM) of the medulla oblongata
Bedtime administration reduces the incidence of orthostatic hypotension from 28% for daytime administration to 7%
When using CYP3A4 inhibitors in combination, blood drug concentration should be monitored to avoid toxicity caused by metabolic inhibition

In vitro experiments have shown that Flibanserin Tablet 100mg has no excitotoxicity to hippocampal neurons
Chronic treatment does not cause upregulation of dopamine D2 receptors in the striatum
No sensitization of the reward system was observed in animal models

The gradual reduction plan (reducing 25mg per week) can reduce the incidence of withdrawal symptoms from 41% to 9%
The combined use of SSRIs can alleviate anxiety withdrawal symptoms
Neuroplasticity changes are reversible, and after 6 months of discontinuation, the activation pattern in the brain area returns to baseline levels